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Opinion statement
Central retinal artery occlusion (CRAO) is an ocular emergency and is the ocular ana-
logue of cerebral stroke. It results in profound, usually monocular vision loss, and is
associated with significant functional morbidity. The risk factors for CRAO are the same
atherosclerotic risk factors as for stroke and heart disease. As such, individuals with
CRAO may be at risk of ischemic end organ damage such as a cerebral stroke. Therefore,
the management of CRAO is not only to restore vision, but at the same time to manage
risk factors that may lead to other vascular conditions. There are a number of therapies
that has been used in the treatment of CRAO in the past. These include carbogen in-
halation, acetazolamide infusion, ocular massage and paracentesis, as well as various
vasodilators such as intravenous glyceryl trinitrate. None of these “standard agents”
have been shown to alter the natural history of disease definitively. There has been
recent interest shown in the use of thrombolytic therapy, delivered either intravenously
or intra-arterially by direct catheterisation of the ophthalmic artery. Whilst a number of
observational series have shown that the recovery of vision can be quite dramatic, two
recent randomised controlled trials have not demonstrated efficacy. On the contrary,
intra-arterial delivery of thrombolytic may result in an increased risk of intracranial
and systemic haemorrhage, while the intravenous use of tissue plasminogen activator
(tPA) was not shown to be efficacious within 24 h of symptom onset. Nevertheless,
both of these studies have shown one thing in common, and that is for treatment
to be effective in CRAO, it must be deployed within a short time window, probably
within 6 h of symptom onset. Therefore, while CRAO is a disease that does not have
a treatment, nevertheless it needs to follow the same principles of treatment as any
other vascular end organ ischaemic disease. That is, to attempt to reperfuse ischemic
tissue as quickly as possible and to institute secondary prevention early.
Introduction
Central retinal artery occlusion (CRAO) is the occlusion
of the central retinal artery (CRA) with resultant infarc-
tion of the retina and vision loss. It was first described
as an embolic occlusion of the CRA in a patient with en-
docarditis by von Graefe in 1859 [1]. The incidence of
CRAO is estimated around 1.9/100,000 in the United
States [2•].
Patients with CRAO typically present with an acute,
painless loss of vision, and 80%of affectedpatients have
a final visual acuity of counting fingers or worse [3, 4].
Visual loss in CRAO occurs as a result of loss of blood
supply to the inner retinal layers. Approximately 15–
30% of the general population have a cilioretinal artery,
which is a branch of the short posterior ciliary artery [5].
It supplies a part or the whole of the fovea, and in those
eyes where there is a CRAO, the cilioretinal artery is
spared and the visual acuity may be preserved at 20/50
or better, with loss of peripheral vision only.
Themost common cause of CRAO is thromboembo-
lus, which occurs at the narrowest part of the central ret-
inal artery, where it pierces the dural sheath of the optic
nerve [6••, 7]. It could also occur as a result of an occlu-
sive thrombus at the level immediately posterior to the
lamina cribrosa [8]. Once the central retinal artery is oc-
cluded, the ability of the retina to recover depends on
whether the offending embolus or thrombus is dis-
lodged, and also on the retinal tolerance time [9, 10].
CRAO is divided into four distinct clinical entities:
(1) Non-arteritic permanent CRAO (Fig. 1)
This group accounts for over two thirds of all CRAO
cases, and is caused by platelet fibrin thrombi
and emboli as a result of atherosclerotic disease
[11–13].
(2) Non-arteritic transient CRAO
Non-arteritic transient CRAO (transient monocu-
lar blindness) accounts for 15 % of CRAOs and
has the best visual prognosis. People suffering
from this have a 1 % risk per year of having a per-
manent non-arteritic CRAO [14]. Transient vaso-
spasm due to serotonin release from platelets on
atherosclerotic plaques has also been suggested
as a mechanism of transient CRAO in animal
models [9].
(3) Non-arteritic CRAO with cilioretinal sparing
(Fig. 2)
Preservation of the cilioretinal artery results in
preserved perfusion of the macula region [4].
(4) Arteritic CRAO (Fig. 3)
Arteritic CRAO (including the vasculitides) accounts
forG5%of cases. Giant cell arteritis is themost com-
mon entity in this category, and can cause bilateral
visual loss. If an arteritic cause is suspected, it is es-
sential to assess the inflammatory markers and treat
urgently with systemic corticosteroids.
Figure 1. Colour fundus photograph show-
ing non-arteritic permanent central retinal
artery occlusion in the right eye and a
normal fundus in the left eye.
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The majority of CRAOs are of the non-arteritic per-
manent type and are analogous to a terminal arterial
branch occlusion in cerebral stroke. In a suspected
non-arteritic CRAO due to thrombo-embolic cause,
evaluation of atherosclerotic risk factors, including a
family history of cerebrovascular and cardiovascular
disease, diabetes mellitus, hyperlipidemia, a past his-
tory of vascular disease, smoking, palpitations, valvu-
lar heart disease or transient ischaemic events such
as transient monocular blindness, transient ischemic
attack (TIA) or angina symptoms, should be sought
[15–22]. In those CRAOs where there are no athero-
sclerotic risk factors, especially in a young patient,
other less common factors should be explored.
These include the presence of vasculitis, sickle cell
disease, myeloproliferative disorders, hypercoagula-
ble states, and the use of the oral contraceptive pill
or illicit drugs [23].
The following discussion on therapy concentrates
mainly on the management of non-arteritic CRAO of
presumed thromboembolic origin that forms the ma-
jority of CRAO cases.
Figure 2. Colour fundus photograph and
fundus fluorescein angiogram of the
right eye showing non-arteritic CRAO with
cilioretinal sparing.
Figure 3. Colour fundus photograph of
the left eye showing arteritic central
retinal artery occlusion; serial fundus
fluorescein angiogram showing delayed
arterial filling and choroidal ischaemia.
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Treatment
Diet & lifestyle
The risk factors for CRAO are those of atherosclerosis [24, 25]. Diet and
lifestyle play a role indirectly for secondary prevention of further end organ
ischemia. Hypertension and diabetes are the most frequent risk factors for
CRAO [24]. Other associated risk factors include smoking, hypercholester-
olemia and a family history of microvascular disease.
As a result, a diet with a low glycemic index would reduce the risk of
vascular disease [26]; such a diet is rich in fruits, vegetables, grains, low-
fat or nonfat dairy products, fish, legumes, poultry, and lean meats,
polyunsaturated fatty acids. Also, regular exercise is essential to reduce
the cardiovascular risk factors [27]. A healthy diet hence plays a role for
secondary prevention in CRAO.
Hyperhomocystinemia is also recognised as a risk factor for CRAO [28],
and results in dysfunction of vessel endothelium, with a proliferation of
vascular smooth muscle and prothrombic hemostatic changes. Homocys-
teine levels are known to increase in a diet deficient in folic acid and vitamin
B6 and B12, and hence diet with adequate folic acid and vitamin B6 and B12
in patients with hyperhomocystinemia would reduce the risk of CRAO.
Pharmacological treatment
The retinal tolerance time to acute ischaemia has been evaluated in experi-
mental studies [29]. These studies suggest that the retina in elderly, athero-
sclerotic and hypertensive rhesus monkeys suffer no detectable damage to
CRAO for 97 min. Thereafter, partial recovery is possible if the ischemia is
reversed up to 240 min. The time when irreversible retinal damage occurs
with no recovery of vision is not known, but postulated to be around 6 to
6.5 h [30•, 31]. Hence, for any treatment to be effective, it is essential to
implement the treatment within the correct time window. Spontaneous re-
canalization of the occluded central retinal artery may occur within 48 h to
72 h, but this may be partial [3]. Current reports on the visual improvement
rate vary from 1 % to 10 % of cases of non-arteritic CRAO [13, 32]. Recent
studies have suggested that the minimally invasive therapy in CRAO do not
result in a significant visual recovery [33, 34].
Table 1 summarises the various available pharmacological options in the
treatment of CRAO.
Vasodilators, which help in increasing the blood oxygen content
Pentoxyphylline [35, 36]
Pentoxyphylline is a tri-substituted xanthine derivative that works by in-
creasing erythrocyte flexibility, reducing blood viscosity, and increasing mi-
crocirculatory flow and tissue perfusion. It has been used in the treatment of
peripheral vascular disease. In a randomised control trial, a small number of
patients (ten patients) with CRAO were randomised to either pentoxiphyl-
line or placebo for 4 weeks. The endpoint measurements include objective
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CRAblood flowmeasuredbyduplex scanning. The authors noted an increase
in the peak systolic and end diastolic flow velocities by 550 % and 400 %,
respectively, in five patients treated with pentoxifylline, versus 288 % and
200 %, respectively, in a placebo group of five patients. However, the visual
recovery was not discussed in the study and the numbers were small [36].
Standard dosage 600 mg tds
Contra indications Allergy to theophylline or caffeine
Main drug interactions Warfarin: Pentoxiphylline increases the anticoagulant effect of warfarin
Theophylline & Aminophylline: When used in combination, pentoxiphylline
potentiates the effect of theophylline and aminophylline
Main side effects Digestive (dry mouth or dehydration, constipation, anorexia, cholecystitis)
Neurogenic (aseptic meningitis, seizures, confusion, depression anxiety),
Cardiovascular (hypotension, edema, dyspnea)
Respiratory (nasal congestion, nosebleed, breathing difficulty)
Dermatological (rash, angioedema, urticaria, pruritus, brittle fingernails)
Ear and eye related (earache, scotoma, conjunctivitis, blurred vision)
Cost / cost effectiveness Pentoxyphylline is inexpensive, but the effectiveness is not established.
Inhalation of carbogen (mixture of 95 % oxygen
and 5 % carbon dioxide)
Carbogen is a mixture of 4–7 % carbon dioxide and 93–96 % oxygen,
used in the treatment of CRAO based on the assumption that carbon
dioxide will prevent oxygen-induced vasoconstriction and hence main-
tain or even improve the blood flow while maintaining the oxygenation
of the retina [37, 38]. Carbogen inhalation is conducted for 10 min every
hour during waking hours, and 10 min every 4 h at night and continued
for 48–72 h. However, retinal dynamics obtained with carbogen have
Table 1. Options available in treatment of central retinal artery occlusion
Group of drugs Mechanism of action












3. Intravenous methylprednisolone Reduction of retinal oedema
4. Nd YAG Laser embolectomy Lyse or dislodge the clot
5. Intra arterial or intravenous
thrombolysis
Help in thrombolysis of the embolus
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been contradictory [39], and the results of visual recovery with carbogen
in acute CRAO was not significant [40].
Hyperbaric oxygen
The proposed role for hyperbaric oxygen in CRAO is an increase the
partial pressure of oxygen delivery to ischemic tissue until sponta-
neous or assisted reperfusion occurs. The exact pathogenesis is de-
bated [41, 42, 43•, 44–46] and the efficacy is not proven. The
protocol for hyperbaric oxygen varies in different studies, with an
average of 2–2.5 atm for approximately 90 min within 8 h of onset
of CRAO [47].
Sublingual isosorbide dinitrite
Nitroglycerin causes relaxation of vascular smooth muscle by stimulating
intracellular cyclic guanosine monophosphate (GMP). Nitroglycerine
has been used in central retinal artery occlusion along with other modes
of treatment, including ocular massage and other means to reduce the
intraocular pressure [48].
Standard dosage 10 mg
Contraindications Hypersensitivity, severe anaemia, recent use of phosphodiesterase inhibitors
Main drug interactions Drugs which decrease the effect of isosorbide dinitrite include:
& Dopamine receptor agonist (Bromocriptine, cabergoline)
& Ergopeptides (dihydroergotamine, ergotamine, methylergonovine,
methysergide)
& Drugs which have an additive vasodilator effect
& Phosphodiesterase inhibitors
Main side effects Common: Headache, hypotension, tachycardia, dizziness, lightheadedness,
blurred vision, flushing, nausea and vomiting, nervousness, xerostomia
Serious: Methemoglobinemia (rare), syncope, prolonged bleeding time,
exfoliative dermatitis, unstable angina, rebound hypertension,
thrombocytopenia
Cost / cost effectiveness Isosorbide dinitrate is inexpensive, but the effectiveness is not established.
Reduction of intraocular pressure, and hence increase the retinal artery perfusion or help dislodge
the embolus
As mean ocular perfusion pressure is the difference between mean arterial
pressure and intraocular pressure, attempts have been made to reduce the in-
traocular pressure and thus increase ocular perfusion [33, 48].
Ocular massage
Ocular massage includes the compression of the globe with a three-
mirror contact lens for 10 s, to obtain retinal artery pulsation or flow
cessation if the pulsation is not seen followed by a 5 s release [16, 48,
49]. Alternatively, digital massage can be applied over the globe over
the closed eyelids for 15–20 min. The combination of the massage
and acetazolamide can decrease the intraocular pressure to as low as
68 NEUROLOGIC OPHTHALMOLOGY AND OTOLOGY (RK SHIN, SECTION EDITOR)
5 mmHg within a short period of time [49]. Ocular massage causes
retinal arterial dilatation and large fluctuations in Intraocular pressure
(IOP). It has been postulated that this activity may mechanically facili-
tate the disintegration of a thrombus, or dislodge an impacted embolus
into a more peripheral part of the retinal circulation [18].
Intravenous acetazolamide
Acetazolamide is a carbonic anhydrase inhibitor that reduces the aque-
ous production and hence reduces the intraocular pressure. This in turn
increases the retinal perfusion [48].
Standard dosage intravenous injection 500 stat or 250 mg qid for 24 h
Contraindications Hypokalemia & hyponatremia, hyperchloremic acidosis, sulfa allergy, liver
or renal disease including liver cirrhosis
Main drug interactions Methenamine: When methenamine is used with acetazolamide, there are
insoluble precipitates in the urine, and this decreases the effect of both drugs
Cisapride: Acetazolamide increases the toxicity of cisapride by passive tu-
bular resorption by increasing the pH
Main side effects CNS: Confusion, Convulsions, Drowsiness, Flaccid paralysis, Malaise
GI: Anorexia, Diarrhea, Metallic taste, Nausea, Vomiting, Hepatic disease,
Melena
Blood: Aplastic anemia, Agranulocytosis, Leukopenia Paresthesia, Throm-
bocytopenia, Thrombocytopenic purpura
Renal: Hematuria, Polyuria,
Electrolyte imbalance, Glycosuria, acidosis
Photosensitivity, Urticaria
Hearing dysfunction or tinnitus
Sulfonamide type reaction
Special points The medication is used as an immediate intravenous or short-term intensive
oral therapy but not designed as a long-term therapy. Hence, the long-term
monitoring in acetazolamide use do not apply in this setting.
Cost / cost effectiveness Acetazolamide is inexpensive.
Intravenous mannitol
Standard dosage 1.5–2 g/ Kg over 30–60 min
Contraindications Hypersensitivity, severe dehydration, anuria, progressive renal disease, severe
pulmonary edema or heart failure, metabolic edema, active intracranial
bleeding
Main drug interactions Tobramycin: Mannitol increases the level of tobramycin by unknown
mechanism
Lurasidone, Nitroglycerine: these can increase the effect of mannitol
Main side effects GI: Nausea, Vomiting





Cost / cost effectiveness Mannitol is inexpensive.
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Topical antiglaucoma drops
Glaucoma medications aim to lower the intraocular pressure and in-
crease the gradient across the optic nerve head (perfusion pressure=mean
arterial pressure – intraocular pressure). The drops act by decreasing
aqueous humor production (with beta-adrenergic blockers or carbonic
anhydrase inhibitors), or increasing outflow (with prostaglandin ana-
logue or an alpha-agonist). However, the onset of action is slow with
topical drops compared to intravenous acetazolamide and mannitol.
Reduction of retinal oedema
Intravenous methylprednisolone
A single dose of intravenous methylprednisolone of 1 g has been
reported in a case series of patients whose vision failed to improve fol-
lowing the conventional treatment of measures to reduce the intraocular
pressure [50, 51]. The possible mechanism of action is reported to be a
reduction in the retinal oedema, and hence, improvement of vision.
However, the patients were younger, and it is possible that these patients
had vasospasm or CRAO secondary to vasculitis, rather than athero-
sclerotic-induced CRAO.
Special consideration Intravenous methylprednisolone is given in suspected arteritic CRAO due to
giant cell arteritis, but is not a recommended treatment for non-arteritic
permanent CRAO.
Thrombolytic therapy
Tissue plasminogen activator (tPA)
Tissue plasminogen activator (tPA) is a naturally occurring fibrinolytic
agent found in vascular endothelial cells and results in clot lysis. At the
site of the thrombus, the binding of tPA and plasminogen to the fibrin
surface induces a conformational change that facilitates the conversion of
plasminogen to plasmin and dissolves the clot.
Alteplase, a recombinant tPA, is a fibrin- specific agent commonly
used in ischaemic stroke, myocardial infarction and massive pulmonary
embolism. CRAO is a stroke of the eye analogous to ischemic cerebral
stroke, and the CRA and retina are homologous to the circle of Willis and
the brain respectively. Fibrinolysis is an accepted standard therapy in the
treatment of ischaemic stroke, and hence there is biological plausibility
for its use in CRAO.
Two large reviews [52, 53] and several observational studies [31, 54, 55]
have suggested that thrombolysis in the treatment of CRAO may improve
the visual acuity with few serious complications. However, data froma large
multicentre randomised study using intra-arterial thrombolysis [56••], and
another randomised study using intravenous thrombolysis [30•] have
failed to show an improvement in the visual acuity.
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Intravenous thrombolytic delivery has the advantage of easier access
without the need for specialized interventional radiology unit and reduced
risk of complications [57]. On the other hand, the disadvantage of an
endovascular intra-arterial approach is the increased risk of strokes, the re-
quirement of a neuro-interventionalist, and a longer procedural time [58].
Not only are the results in various studies debatable, there is a marked
heterogeneity of drug regimens, pre-treatment and post-treatment evalua-
tion, and the therapeutic window (time from the onset of visual loss to drug
infusion), which make it very difficult to draw conclusions from the pub-
lished studies [59].
Specific drugs Various thrombolytic agents have been indicated in different studies. Most
often, tPA or urokinase are used.
Standard dosage Intravenous tPA dose varied from a loading dose of 50 mg infusion over
60 min (a dose smaller than recommended in ischaemic stroke) to
0.9 mg/ Kg (maximum of 90 mg) that is the standard dose used in is-
chemic stroke [59]. The use of adjuvant therapy, such as heparin with
intravenous heparin, or anti-platelet therapy is not standardized, and
was greatly varied between the various studies to allow comparison and
comment.
Contraindications [61]
& Evidence of intracerebral hemorrhage on pre-treatment evaluation
& Suspicion of subarachnoid hemorrhage on pretreatment evaluation
& Myocardial infarction, Intracranial or intraspinal surgery, serious head
trauma or stroke in the last 3 months
& Gastro-intestinal or genito-urinary haemorrhage in the previous 3 weeks
& Early ischaemic changes occupying greater than one-third of the middle
cerebral artery (MCA) territory
& History of intracerebral hemorrhage (ICH)
& Uncontrolled hypertension at time of treatment (9185 mmHg systolic or
9110 mmHg diastolic)
& Blood glucose 922.22 mmol [62]
& NIH Stroke scale score 925 [62]
& Seizure at onset of stroke
& Active internal bleeding
& Intracranial neoplasm, arteriovenous malformation, or aneurysm
& Known bleeding diathesis, including but not limited to :
& Current use of oral anticoagulants such as Warfarin or an International
normalised ratio (INR) of 91.7, prothrombin time (PT) of 915 s
& Administration of heparin within 48 h preceding the onset of the
stroke and a elevated activated partial thromboplastin time (aPTT) at
presentation
& Platelet count G100,000 mm2
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Main drug interactions [61] Increased risk of bleeding with the concomitant or immediate prior use of
anti-coagulant, anti-platelet or vitamin K antagonists.
No studies on interactions of tPA and other cerebroactive drugs.
Main side effects [61] Intracerebral and systemic haemorrhage
The following have been reported in clinical trials and post marketing experience
involving tPA: anaphylactoid reaction, laryngeal edema, orolingual angioedema
(often due to concomitant use of ace-inhibitors), rash and urticaria.
Specific to ischaemic stroke: cerebral edema, cerebral herniation, seizure,
new ischaemic stroke.
Special considerations The role of adjuvant therapy with thrombolysis is not known. There is no
consensus with regard to the standard dose, route of administration or si-
multaneous use of heparin in various studies. The EAGLE study used intra-
arterial tPA within 24 h of visual loss followed by heparin for 5 days [60].
Cost / cost effectiveness The agent tPA cost approximately USD $1,487.06 per 50 mg vial and
$2,974.13 per 100 mg vial (including diluent) [63]. It requires specialized
neuro-intervention set-up and neuroradiologist for intra-arterial adminis-
tration, or specialized stroke unit set-up for intra-arterial administration.
Cost effectiveness has not been established in CRAO. However, a recent
systematic review in The American Journal of Managed Care on cerebral
ischaemic stroke has built upon primary cost effectiveness data from Fagan
and colleagues in 1998 [64, 65]. The study used data from the NINDS rt-PA
Study [66] and medical literature to estimate health and economic outcomes
in ischaemic stroke patients treated with rt-PA. A Markov model was then
developed to estimate costs per 1,000 patients eligible for rt-PA vs. costs per
1,000 people untreated [64]. The estimated impact of rt-PA use on long term
health outcomes was a savings of 564 quality-adjusted life years (QALYs)
over 30 years in the 1,000 person model [64].
Cost effective calculations showed rt-PA treatment resulted in incremental
cost savings of $8,000 per QALY gained. Using Fagan’s cost saving result at
$600 per rt-PA treated, it was estimated that in 2005, for every 2 % increase
in the proportion of ischaemic stroke patients receiving rt-PA, the result was
$7 million dollars of annual healthcare cost savings in the USA [67].
Surgery/procedures
Lowering intraocular pressure to increase optic nerve head perfusion gradient
Anterior chamber paracentesis
This is achieved by inserting a 27-gauge needle into the anterior chamber
via the limbus and withdrawing 0.1 ml to 0.2 ml of aqueous fluid. The
potential benefits of paracentesis include a dramatic drop in IOP, and
dilatation of the retinal arteries because of the vascular tortuosity
resulting from distortion of the globe [49]. However, a maximum in-
crease in retinal arterial volume flow of only 20 % has been estimated
from animal studies, and a rise in perfusion pressure of less than 15 % is
expected when the IOP falls from 15 mmHg to 5 mmHg [18, 40].
Complication The potential risk of paracentesis includes infection.
Special points The procedure is well described and commonly employed [62], but the ef-
fectiveness is not proven.
Cost The cost of the procedure is inexpensive.
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Means to lyse and dislodge the embolus
Nd YAG laser (Neodymium:yttrium-aluminum-garnet laser)
A single case report has been reported with an improvement of vision fol-
lowing the use ofNdYAG laser in a patient withCRAO. The laser, using 0.8–
1.1 mJ intensity, was focused slightly posterior to the visible arterial wall at
the site of the embolus [68, 69]. The laser tends to dislodge the embolus,
which dissolves later. The complication of the laser includes vitreous
hemorrhage and false aneurysm. Since these are only case reports and the
procedure involves significant complications, YAG laser embolectomy is
not accepted as a standard treatment of choice in CRAO.
Pars plana vitrectomy
A pars plana vitrectomy followed by removal of the embolus has been
shown to be promising in case reports [70, 71] and small case series
[72]. It has been suggested to perform a fluorescein angiogram to
ascertain the site of occlusion, and a longitudinal incision is made
over the area of occlusion to remove the embolus. However, the
studies are limited and randomised control studies are required to
ensure the safety of the treatment of this procedure in CRAO.
Complications Vitreous haemorrhage
Cataract
Special points This procedure is not a standard acute treatment for CRAO.
Cost/cost effectiveness Expensive when considering the cost of surgery and expertise required. The
treatment is not proven, and hence not cost effective.
Neovascularisaion following CRAO
Treatment of neovascularization
Neovascularization (Fig. 4) followed by glaucoma occurs in 2.5–31.6 %, and the
mean time from CRAO to observed neovascularization was 8.5 weeks (range 2–
16 weeks) [73]. Rudkin et al. reported a definite temporal relationship between
the CRAO and neovascularization events in 18.2 % of patients, with no other
causes of neovascularization demonstrable in their cohort of patients. In the
majority of cases of neovascularisation, there were no clinical features of ocular
Figure 4. Colour fundus photograph and
fundus fluorescein angiogram of the left
eye showing neovascularisation of the
disc where the new vessel result in
leakage and bright hyper-fluorescence at
the disc.
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ischemia, and no association with a hemodynamically significant stenosis of the
carotid artery. It is essential to review all patients with acute CRAO at regular
intervals as early as 2 weeks, then monthly up to 4 months, post-CRAO. If at any
stage, a patient develops neovascularisation, panretinal photocoagulation should
be performed promptly. Pan-retinal photocoagulation aims to decrease demand
for oxygen in the peripheral retina to reduce the vascular endothelial vascular
growth factors that cause abnormal blood vessel. The newvessels, if left untreated,
can bleed easily into the eye and result in vitreous hemorrhage or high pressure in
the eye (neovascular glaucoma).
Conclusion
CRAO should be considered as an ocular emergency and is the ocular analogue of
cerebral stroke. The same atherosclerotic risk factors that predispose to cardio,
peripheral and cerebrovascular diseases are present in CRAO, and these must be
actively evaluated to prevent further medical comorbidities. Current acute man-
agements in acute CRAO have limited efficacy to improve vision and studies
suggest that for treatment to be effective in CRAO, it must be deployed within a
short time window, potentially within 6 h of symptom onset within the retinal
tolerance time for any therapy to be effective. Current management follows the
same principles of treatment as any other vascular end organ ischaemic disease,
and includes vascular review to prevent further end organ ischemia and ocular
complications.
Disclosure
No potential conflicts of interest relevant to this article were reported.
Open Access
This article is distributed under the terms of the Creative Commons Attribution License which permits any use,
distribution, and reproduction in any medium, provided the original author(s) and the source are credited.
References and Recommended Reading
Papers of particular interest, published recently, have been
highlighted as:
• Of importance
•• Of major importance
1. Graefes AV. Ueber Embolie der Arteria centralis reti-
nae als Ursache plotzlicher Erblindung. Arch Oph-
thalmol;5:136–157
2.• Leavitt JA, Larson TA, Hodge DO, Gullerud RE. The
incidence of central retinal artery occlusion in
Olmsted County, Minnesota. Am J Ophthalmol.
2011;152:820–3.
This is a large retrospective study which determines the in-
cidence of central retinal artery occlusion.
3. Rumelt S, Brown GC. Update on treatment of retinal
arterial occlusions. Curr Opin Ophthalmol.
2003;14:139–41.
4. Hayreh SS, Zimmerman MB. Central retinal artery
occlusion: visual outcome. Am J Ophthalmol.
2005;140:376–91.
5. Lorentzen S. Incidence of cilioretinal arteries. Acta
Ophthalmol. 1970;48:518–24.
74 NEUROLOGIC OPHTHALMOLOGY AND OTOLOGY (RK SHIN, SECTION EDITOR)
6.•• Hayreh S. Acute retinal arterial occlusive disorders.
Progr Retin Eye Res. 2011;30:359–94.
This review article details the anatomy of the blood
supply to the eye. The classification of acute retinal ar-
terial ischaemic disorders and their management are
discussed.
7. Hayreh S. A Study of the Central Artery of the
Retina in Human Beings in its Intra-orbital and
Intra-neural Course: Thesis for Master of Surgery,
Panjab University, India, 1958. Back to cited text,
1958.
8. Mangat HS. Retinal artery occlusion. Surv Ophthal-
mol. 1995;40:145–56.
9. Hayreh SS. Prevalent misconceptions about acute
retinal vascular occlusive disorders. Progr Retin Eye
Res. 2005;24:493–519.
10. Hayreh S, Kolder H, Weingeist T. Central retinal ar-
tery occlusion and retinal tolerance time. Ophthal-
mology. 1980;87:75.
11. Chen CS, Lee AW. Management of acute central ret-
inal artery occlusion. Nat Clin Pract Neurol.
2008;4:376–83.
12. Rudkin A, Lee A, Chen C. Vascular risk factors for
central retinal artery occlusion. Eye. 2009;24:678–81.
13. Schmidt DP, Schulte-Mönting J, Schumacher M.
Prognosis of central retinal artery occlusion: local
intraarterial fibrinolysis versus conservative treat-
ment. Am J Neuroradiol. 2002;23:1301–7.
14. Kline L. The natural history of patients with amau-
rosis fugax. Ophthalmol Clinics of N Am.
1996;9:351–8.
15. Savino PJ, Glaser JS, Cassady J. Retinal stroke: is the
patient at risk? Arch Ophthalmol. 1977;95:1185.
16. Augsburger J, Magargal L. Visual prognosis following
treatment of acute central retinal artery obstruction.
Br J Ophthalmol. 1980;64:913–7.
17. Pfaffenbach D, Hollenhorst R. Morbidity and survi-
vorship of patients with embolic cholesterol crystals
in the ocular fundus. Trans Am Ophthalmol Soc.
1972;70:337.
18. Ffytche T. A rationalization of treatment of central
retinal artery occlusion. Trans Ophthalmol Soc U K.
1974;94:468–79.
19. Wang FM, Henkind P. Visual system involvement in
giant cell (temporal) arteritis. Surv Ophthalmol.
1979;23:264–71.
20. McBrien D, Bradley R, Ashton N. The nature of reti-
nal emboli in stenosis of the internal carotid artery.
Lancet. 1963;281:697–9.
21. Cogan DG, Kuwabara T, Moser H. Fat emboli in the
retina following angiography. Arch Ophthalmol.
1964;71:308–13.
22. David NJ, Lintworth GK, Friedberg SJ, Dillon M. Fetal
atheromatous cerebral embolism associated with
bright plaques in the retinal arterioles. Report of a
case. Neurology. 1963;13:708–13.
23. Greven CM, Slusher MM, Weaver RG. Retinal arterial
occlusions in young adults. Am J Ophthalmol.
1995;120:776–83.
24. Schmidt D, Hetzel A, Geibel-Zehender A, Schulte-
Monting J. Systemic diseases in non-inflammatory
branch and central retinal artery occlusion-an over-
view of 416 patients. Eur J Med Res. 2007;12:595–
603.
25. Hayreh SS, Piegors DJ, Heistad DD. Serotonin-in-
duced constriction of ocular arteries in atheroscle-
rotic monkeys: implications for ischemic disorders of
the retina and optic nerve head. Arch Ophthalmol.
1997;115:220–8.
26. Hjermann I, Velve BK, Holme I, Leren P. Effect of diet
and smoking intervention on the incidence of coro-
nary heart disease. Report from the Oslo Study
Group of a randomised trial in healthy men. Lancet.
1981;2:1303–10.
27. Pearson TA, Blair SN, Daniels SR, et al. AHA
guidelines for primary prevention of cardiovascu-
lar disease and stroke: 2002 update consensus
panel guide to comprehensive risk reduction for
adult patients without coronary or other athero-
sclerotic vascular diseases. Circulation.
2002;106:388–91.
28. Sottilotta G, Oriana V, Latella C, et al. Role of
hyperhomocystinemia in retinal vascular occlusive
disease. Clin Appl Thromb Hemost. 2007;13:104–7.
29. Hayreh SS, Zimmerman MB, Kimura A, Sanon A.
Central retinal artery occlusion: retinal survival time.
Exp Eye Res. 2004;78:723–36.
30.• Chen CS, Lee AW, Campbell B, et al. Efficacy of
intravenous tissue-type plasminogen activator in
central retinal artery occlusion. Stroke.
2011;42:2229–34.
This study highlights that intravenous tPA has minimal effect
in patients diagnosed to have CRAO, especially if adminis-
tered after the window period of 6 hours. The study also
highlights the increased risk of reocclusion in these patients.
31. Hattenbach LO, Kuhli-Hattenbach C, Scharrer I,
Baatz H. Intravenous thrombolysis with low-dose
recombinant tissue plasminogen activator in central
retinal artery occlusion. Am J Ophthalmol.
2008;146:700–6. e701.
32. Beatty S, Eong KGA. Local intra-arterial fibrinolysis
for acute occlusion of the central retinal artery: a
meta-analysis of the published data. Br J Ophthal-
mol. 2000;84:914–6.
33. Landa E, Rehany U, Rumelt S. Visual functions fol-
lowing recovery from non-arteritic central retinal ar-
tery occlusion. Ophthalmic Surg Laser Imag.
2004;35:103.
34. Mueller AJ, Neubauer AS, Schaller U, Kampik A.
Evaluation of minimally invasive therapies and ra-
tionale for a prospective randomized trial to evaluate
selective intra-arterial lysis for clinically complete
Treatment Options for Central Retinal Artery Occlusion Cugati et al. 75
central retinal artery occlusion. Arch Ophthalmol.
2003;121:1377–81.
35. Incandela L, Cesarone M, Belcaro G, et al. Treatment of
vascular retinal disease with pentoxifylline: a con-
trolled, randomized trial. Angiology. 2002;53:31–4.
36. Fraser SG, Adams W. Interventions for acute non-
arteritic central retinal artery occlusion. Cochrane
Database Syst Rev 2009;1.
37. Arend O, Harris A, Martin BJ, Holin M, Wolf S. Ret-
inal blood velocities during carbogen breathing using
scanning laser ophthalmoscopy. Acta Ophthalmol.
1994;72:332–6.
38. Harino S, Grunwald JE, Petrig BJ, Riva CE.
Rebreathing into a bag increases human retinal
macular blood velocity. Br J Ophthalmol.
1995;79:380–3.
39. Deutsch TA, Read JS, Ernest JT, Goldstick TK. Effects
of oxygen and carbon dioxide on the retinal vascu-
lature in humans. Arch Ophthalmol.
1983;101:1278–80.
40. Atebara NH, Brown GC, Cater J. Efficacy of ante-
rior chamber paracentesis and Carbogen in treat-
ing acute nonarteritic central retinal artery
occlusion. Ophthalmology. 1995;102:2029–34.
discussion 2034–2025.
41. Aisenbrey S, Krott R, Heller R, Krauss D, Rössler G,
Heimann K. Hyperbaric oxygen therapy in retinal
artery occlusion. Ophthalmologe: Zeitschrift der
Deutschen Ophthalmologischen Gesellschaft.
2000;97:461–7.
42. Menzel-Severing J, SiekmannU,Weinberger A, Roessler
G, Walter P, Mazinani B. Early hyperbaric oxygen
treatment for nonarteritic central retinal artery ob-
struction. Am J Ophthalmol. 2012;153:454–9.
43.• Cope A, Eggert J, O'Brien E. Retinal artery occlu-
sion: visual outcome after treatment with hyper-
baric oxygen. Diving Hyperb Med. 2011;41:135–8.
This case series discusses the visual outcome of patients
treated with hyperbaric oxygen therapy in CRAO.
44. Hertzog L, Meyer G, Carson S, Strauss M, Hart G. C
treated with hyperbaric oxygen. Undersea Hyperb
Med. 1992.
45. Weiss JN. Hyperbaric oxygen treatment of nonacute
central retinal artery occlusion. Undersea Hyperb
Med. 2010;37:167–72.
46. Anderson Jr B, Saltzman HA, Heyman A. The effects
of hyperbaric oxygenation on retinal arterial occlu-
sion. Arch Ophthalmol. 1965;73:315–9.
47. Butler Jr F, Hagan C, Murphy-Lavoie H. Hyperbaric
oxygen therapy and the eye. Undersea Hyperb Med.
2008:333–387
48. Rumelt S, Dorenboim Y, Rehany U. Aggressive sys-
tematic treatment for central retinal artery occlusion.
Am J Ophthalmol. 1999;128:733–8.
49. Beatty S, Eong KGA. Acute occlusion of the retinal
arteries: current concepts and recent advances in di-
agnosis and management. Emerg Med J.
2000;17:324–9.
50. Hausmann N. High dose steroid bolus given for oc-
clusion of central retinal artery: author’s reply. Br
Med J. 1992;304:506–7.
51. Pandit JC, Tiamiyu F. High dose steroid bolus given
for occlusion of central retinal artery. BMJ: Br Med J.
1992;304:506–7.
52. Biousse V, Calvetti O, Bruce BB, Newman NJ.
Thrombolysis for central retinal artery occlusion. J
Neuro Ophthalmol. 2007;27:215–30.
53. Noble J, Weizblit N, Baerlocher M, Eng K. Intra-arterial
thrombolysis for central retinal artery
occlusion: a systematic review. Br J Ophthalmol.
2008;92:588–93.
54. Aldrich EM, Lee AW, Chen CS, et al. Local Intraarte-
rial fibrinolysis administered in aliquots for the
treatment of central retinal artery occlusion. Stroke.
2008;39:1746–50.
55. ZhangX, Ji X, LuoY, et al. Intra-arterial thrombolysis for
acute central retinal artery occlusion. Neurol Res.
2009;31:385–9.
56.•• Schumacher M, Schmidt D, Jurklies B, et al. Central
retinal artery occlusion: local intra-arterial fibrinoly-
sis versus conservative treatment, a multicenter ran-
domized trial. Ophthalmology 2010;117:1367–
1375. e1361.
This randomised multicentre study compares the treatment
outcomes of conventional treatment versus intra-arterial tPA
in patients with CRAO.
57. Lindsberg PJ, Mattle HP. Therapy of basilar artery
occlusion a systematic analysis comparing intra-ar-
terial and intravenous thrombolysis. Stroke.
2006;37:922–8.
58. Arnold M, Koerner U, Remonda L, et al. Comparison
of intra-arterial thrombolysis with conventional
treatment in patients with acute central retinal artery
occlusion. J Neurol Neurosurg Psychiatr.
2005;76:196–9.
59. Biousse V. Thrombolysis for acute central retinal ar-
tery occlusion: is it time? Am J Ophthalmol.
2008;146:631.
60. Feltgen N, Neubauer A, Jurklies B, et al. Multicenter
study of the European Assessment Group for Lysis in
the Eye (EAGLE) for the treatment of central retinal
artery occlusion: design issues and implications. EA-
GLE Study report no. 1. Graefes Arch Clin Exp
Ophthalmol. 2006;244:950–6.
61. Genentech. (2011). Activase, Alteplase, a recombi-
nant tissue plasminogen activator. Available: http://
www.gene.com/gene/products/information/
cardiovascular/activase/. Last accessed 16/8/12.
62. Derex L, Nighoghossian N. Intracerebral haemor-
rhage after thrombolysis for acute ischaemic stroke:
an update. J Neurol Neurosurg Psychiatr.
2008;79:1093.
76 NEUROLOGIC OPHTHALMOLOGY AND OTOLOGY (RK SHIN, SECTION EDITOR)
63. PDR Staff. 2004 Red Book Pharmacy's Fundamental
Reference. 2004th ed. Montvale: Thomson Health-
care; 2004. p183.
64. Fagan S, Morgenstern L, Petitta A, et al. Cost-effective-
ness of tissue plasminogen activator for acute ischemic
stroke. Neurology. 1998;50:883–90.
65. Demaerschalk BM, Hwang HM, Leung G. Cost anal-
ysis review of stroke centers, telestroke, and rt-PA.
Am J Manag Care. 2010;16:537.
66. Tissue plasminogen activator for acute ischemic
stroke. The National Institute of Neurological Dis-
orders and Stroke rt-PA Stroke Study Group. N Engl J
Med 1995;333:1581–1587.
67. Demaerschalk BM, Yip TR. Economic benefit
of increasing utilization of intravenous tissue
plasminogen activator for acute ischemic stroke in
the United States. Stroke. 2005;36:2500–3.
68. Reynard M, Hanscom TA. Neodymium: yttrium-alu-
minum-garnet laser arteriotomy with embolectomy
for central retinal artery occlusion. Am J Ophthalmol.
2004;137:196–8.
69. Haritoglou C, Wolf A, Ulbig MW. Laser embolectomy
for central retinal artery occlusion. Ophthalmologe.
2010;107:465–7.
70. Tang WM, Topping TM. Vitreous surgery for central ret-
inal artery occlusion. Arch Ophthalmol. 2000;118:
1586–7.
71. Peyman GA, Gremillion CM. Surgical removal of a
branch retinal artery embolus: a case report. Int
Ophthalmol. 1990;14:295–8.
72. Garcia-Arumi J, Martinez-Castillo V, Boixadera A,
Fonollosa A, Corcostegui B. Surgical embolus re-
moval in retinal artery occlusion. Br J Ophthalmol.
2006;90:1252–5.
73. Rudkin AK, Lee AW, Chen CS. Ocular neovasculari-
zation following central retinal artery occlusion:
prevalence and timing of onset. Eur J Ophthalmol.
2010;20:1042–6.
Treatment Options for Central Retinal Artery Occlusion Cugati et al. 77
